Author Archive: Jeremy Parkinson

Trump Releases Tax Reform Guidelines

Trump Releases Tax Reform Guidelines

In the lead up to the tax plan announcement, I made the point that if Trump was vague about his plan, stocks would rally on hope. Trump was vague, but it didn’t boost stocks because he was vague on the most important point stocks care about which is the repatriation tax holiday. Stocks care about […]
A 15% Tax On Freelancer Income Would Be Yuuuge

A 15% Tax On Freelancer Income Would Be Yuuuge

President Trump finally came out with his tax plan. Overall it’s a solid plan, though it was pretty much what was expected, given the market response. The new rates themselves are pretty standard; Trump wants 3 brackets topping out at 35%, sweetened with a doubling of the standard deduction to $12,600 per taxpayer. Decent, but […]
“Don’t Believe The Hype”: 2 Charts Suggest Central Banks Are Not All Powerful

“Don’t Believe The Hype”: 2 Charts Suggest Central Banks Are Not All Powerful

Here at HR, we like to present both sides of the argument when it comes to markets. When it comes to politics, we like to present both sides of the story (hey look, it’s not our fault that the political story is one-sided right now – after all, we didn’t write it). Unfortunately, we can’t say […]
Misunderstanding GDXJ: Why It’s Actually Great News For Junior Miners

Misunderstanding GDXJ: Why It’s Actually Great News For Junior Miners

Something extraordinarily good for junior precious metals miners just happened. But for some reason it’s being misinterpreted as a bad thing. Here’s the general story: A Small-Cap Gold Mining ETF Streaks Lower As Big Index Change Looms (Investors.com) – Mining stocks blazed a bright trail of returns since the start of 2016 as gold saw […]
Great Graphic: Gas And Oil

Great Graphic: Gas And Oil

This Great Graphic, made on Bloomberg, shows the past six months of oil and gas prices. The white line is the June gasoline futures and the yellow line is the June light sweet crude oil futures contract. In order to avoid showing two time series with two different scales, which often is an exercise in curve fitting, […]
Another Day, Another USD/CAD Advance

Another Day, Another USD/CAD Advance

The Canadian dollar remains under pressure. The pair reached a new high at 1.3670, reaching yet another 14-month high. The next level of resistance is only at 1.3850. The last time the pair saw these levels was in the wake of 2016. The crash in oil prices sent Dollar/CAD shooting all the way to 1.4690. Yet the fall […]
EC
                        
                        Europe Will Climb That Same Wall Of Worry

EC Europe Will Climb That Same Wall Of Worry

Although sentiment towards European equities has improved since I wrote about it last Fall (pretty sure I am alone in this trade), this opportunity is not something that will be quickly arbitraged away. Not only that, but deep down, investors are still skeptical about the long term prospects for European equities. Sure, they are willing […]
The Biggest Afternoon In Earnings Kicks Off At 4pm: AMZN, GOOGL, MSFT, GPRO, EXPE, SBUX, INTC

The Biggest Afternoon In Earnings Kicks Off At 4pm: AMZN, GOOGL, MSFT, GPRO, EXPE, SBUX, INTC

Seven big names within the tech and consumer discretionary spaces release earnings results this afternoon. Here’s what we’re expecting: Amazon.com Inc. (AMZN) – Consumer Discretionary – Internet & Catalog Retail Key Takeaways The Estimize consensus is calling for earnings per share of $1.12 on $35.55 billion, about 9 cents higher than Wall Street on the bottom […]
Spectacular 7 Year Auction: Record Indirects, Soaring Bid To Cover

Spectacular 7 Year Auction: Record Indirects, Soaring Bid To Cover

After a strong 2 Year on Tuesday, poor 5 Year on Wednesday we close the week with the Treasury’s sale of $28 billion in 7 Year paper in what can only be described as a spectacular auction. The high yield priced at 2.084%, stopping 2bps through the 2.104%, the biggest gap between the two going […]
RedHill’s R&D Day Highlights Potential For Bekinda

RedHill’s R&D Day Highlights Potential For Bekinda

On April 27, 2017, RedHill Biopharma Ltd (NASDAQ: RDHL) held an R&D Day highlighting for investors the clinical and commercial attributes of BEKINDA® (RHB-102). BEKINDA is an oral, extended-release, once-daily formulation of the antiemetic drug ondansetron. The drug is currently being examined as a treatment for acute gastroenteritis and gastritis in a Phase 3 clinical trial […]